Tests a dendritic cell vaccine for brain tumors in children and adults
Tests an immune-based vaccine in people with brain cancer called glioblastoma or DIPG.
Plain-language title generated from the registry record
Registry title: Immune Modulatory DC Vaccine Against Brain Tumor
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with brain cancer (glioblastoma or diffuse intrinsic pontine glioma) who still have a measurable tumour in the brain and have had standard treatment.
- Age
- The criteria say 6 months to 80 years; the registry header lists 1 Year to 75 Years.
- Sex
- All sexes can join.
- Disease stage
- Glioblastoma (GBM) or diffuse intrinsic pontine glioma (DIPG) with existing or measurable tumours in the brain. Seizures must be well controlled. Karnofsky performance score of 60 or more and life expectancy of more than 3 months.
- Earlier treatment
- People must have had standard care, such as full tumour removal with radiotherapy and chemotherapy (about 54 - 60 Gy, TMZ). Gliadel implant within 4 weeks before the study or antibody-based therapies are not allowed.
Main reasons for not taking part
- Autoimmune disease, or long-term need for hormones or immunosuppressive drugs
- HIV, or active HBV or HCV
- Pregnant or breastfeeding women
- Active infection with fever, or uncontrolled infection
- Dexamethasone above 4 mg/day during blood cell collection
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 75 years old?
Source: NCT03914768, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT03914768
- Record updated
- 30 October 2026
- Original description
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including neoantigens to inject into patients. Vaccine-induced T cell responses have been associated with improved survival. The study will evaluate the safety and potential benefit of the novel immunomodulatory DC vaccines.Read full original descriptionShow less
Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM)
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including neoantigens to inject into patients. Vaccine-induced T cell responses have been associated with improved survival. The study will evaluate the safety and potential benefit of the novel immunomodulatory DC vaccines.
Inclusion: Abilities to understand and the willingness to provide written informed consent. Assent will be obtained when appropriate based on the subjects age; Patients are ≥ 6 months and ≤ 80 years old; DIPG or GBM patients with existing or measurable tumors in the brain. Patients have received standard care of medication, such as gross total resection with concurrent radio chemotherapy (~54 - 60 Gy, TMZ); Patients with adequate neurological function and epileptic symptoms that are well controlled; Observing the condition after surgery or without surgery; Karnofsky performance score (KPS) ≥ 60;Life expectancy >3 months; Important organ function is satisfied: Cardiac ultrasound indicates a cardiac ejection fraction ≥50%; and there is no obvious abnormality in the electrocardiogram; blood oxygen saturation ≥90%; creatinine <2.5 times normal range; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 times normal range; Total bilirubin ≤ 2.0 mg / dl; Hgb (hemoglobin) ≥ 80g / L; Peripheral blood absolute lymphocyte count must be above 0.8×10\^9/L; Adequate Neurologic Function Defined as: Patients with seizure disorder may be enrolled if seizure disorder is well controlled; Patients must be willing to follow the orders of doctors.
Exclusion: A prior history of gliadel implantation 4 weeks before this study start or antibody based therapies; The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection; Patients who had previously been treated with cell therapy but were ineffective after physical examination were discussed and confirmed by team experts and were not suitable for re-treatment; Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs; Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products; Active infection with fever; Infection with bacteria, fungi or viruses, uncontrolled; Patients with HIV and those living with active HBV and HCV; Important organ failure (heart, liver, kidney, lung); Patients with neutropenia (> 10 days) that are difficult to correct after treatment; Pregnant, pregnant and lactating women; Anything that researchers believe may increase the risk of subjects or interfere with test results.